Ondansetron Generics [uk]

Ondansetron, the active ingredient in Ondansetron Generics, is a 5‑HT3 receptor antagonist presented as an injectable solution for intravenous use. It is employed to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy and surgery in adult patients. GNH USA supplies Ondansetron Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on the serotonin pathway to control nausea and vomiting in several clinical settings.

Chemotherapy-induced nausea and vomiting: prevents and treats nausea and vomiting associated with cytotoxic chemotherapy. Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. Radiotherapy-induced nausea and vomiting: helps control nausea and vomiting caused by radiotherapy.

Common Side Effects: - Headache - Constipation - Diarrhoea - Dizziness - Fatigue - Injection site reactions

Serious or Rare Side Effects: - QT interval prolongation - Severe allergic reactions (anaphylaxis) - Serotonin syndrome - Cardiac arrhythmias - Severe hypotension - Hepatic dysfunction

Precautions should be observed when using ondansetron to ensure patient safety.

Pregnancy: Category B – use only if the clinical benefit justifies the potential risk to the fetus. Breastfeeding: Caution – the drug may be excreted in breast milk. Renal impairment: Dose adjustment may be required in patients with reduced renal function. Cardiac risk: Monitor QT interval in patients with known cardiac disease or electrolyte disturbances. Drug interactions: Review concomitant medications for serotonergic agents and other QT‑prolonging drugs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ondansetron may interact with several medicines; careful assessment is needed.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension. - Other 5‑HT3 antagonists: additive antiemetic effect may increase toxicity. - Cisapride: risk of QT prolongation. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): potential for serotonin syndrome. - Antifungal azoles (ketoconazole, itraconazole): may increase ondansetron plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise drug concentrations. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Anticholinergics: may exacerbate constipation. - Diuretics: may increase risk of electrolyte imbalance.